Objective: To examine the diversity in paediatric vision and hearing screening programmes in Europe. Methods: Themes for comparison of screening programmes derived from literature were used to compile three questionnaires on vision, hearing, and public health screening. Tests used, professions involved, age, and frequency of testing seem to influence sensitivity, specificity, and costs most. Questionnaires were sent to ophthalmologists, orthoptists, otolaryngologists, and audiologists involved in paediatric screening in all EU full-member, candidate, and associate states. Answers were crosschecked. Results: Thirty-nine countries participated; 35 have a vision screening programme, 33 a nation-wide neonatal hearing screening programme. Visual acuity (VA) is measured in 35 countries, in 71% of these more than once. First measurement of VA varies from three to seven years of age, but is usually before age five. At age three and four, picture charts, including Lea Hyvarinen, are used most; in children over four, Tumbling-E and Snellen. As first hearing screening test, otoacoustic emission is used most in healthy neonates, and auditory brainstem response in premature newborns. The majority of hearing testing programmes are staged; children are referred after 1-4 abnormal tests. Vision screening is performed mostly by paediatricians, ophthalmologists, or nurses. Funding is mostly by health insurance or state. Coverage was reported as >95% in half of countries, but reporting was often not first-hand. Conclusion: Largest differences were found in VA charts used (12), professions involved in vision screening (10), number of hearing screening tests before referral (1-4), and funding sources (8).
Introduction
Childhood sensory functions play a key role in intellectual and social development. Vision or hearing impairment affects both personal and societal health of children. Earlier detection of visual or hearing deficits improve outcome. [1] [2] [3] [4] Vision and hearing screening programmes are based on the same general principles, but vary both within and across European Union (EU) countries, regarding tests used, age of testing, frequency of testing, professions involved in screening, referral procedure, funding, and coverage. Such differences can result in health inequities. No screening, or screening with little population coverage, can result in delayed provision of the correct treatment and increased disease burden. Excessive screening can result in inappropriate interventions and increased costs for health care systems.
Vision screening and subsequent treatment has reduced the occurrence of insufficiently detected and treated amblyopia. 5 In the Netherlands, amblyopia is now detected more than two years earlier than in the 1970s. 6 Early screening and detection of hearing disorders, and timely intervention (eg. cochlear implantation or hearing aid) largely prevents delayed language development, 1, 2, 7 and also improves general developmental outcome at age 3-5. 3 Despite increased consciousness that vision and hearing screening is effective, differences exist in implementation between countries. A 2002 survey of vision screening programmes in 190 countries found that screening was often state funded, visual acuity (VA) was always tested, and that in the EU screening was predominantly voluntary. 8 In a 2012 survey of the International Orthoptic Association, 98% of responders indicated that vision screening programmes existed in their country, (44% were national programmes). Screening was performed by a wide range of professionals. 9 An overview of universal newborn hearing screening (UNHS) in 24 European countries from [2004] [2005] [2006] showed that in several countries UNHS programmes reached more than 95% of all neonates, but in many other countries programmes were recently introduced or were only partially functioning. 10 Other reports on national neonatal hearing screening programmes raise issues on implementation, test procedures, type of tests, coverage, detected cases of hearing loss, and costs. [11] [12] [13] [14] [15] [16] [17] [18] [19] A Health Technology Assessment review in 2008 20 re-examining the cost-effectiveness of vision screening up to age 4-5 (following previous report in 1997 21 ) found that, based on the accepted value of a Quality-adjusted life year, the cost-effectiveness of screening for amblyopia depends on the long-term utility effects of unilateral vision loss and that there was currently no sustainable evidence of utility loss that would render any form of screening likely to be cost-effective. 20 Keren et al. concluded that UNHS in general has the potential for long-term cost savings compared with selective hearing screening and no screening. 22 Burke et al found that the cost-effectiveness of hearing screening depended mainly on the cost of the screening intervention per patient and on the prevalence of hearing loss in the population. 23 We aimed to compile an inventory of population-based vision and hearing screening programmes for children in Europe, and to quantify and examine the differences. This study should assist those countries without a screening programme and new EU member states in selecting which screening protocol to adopt. If large differences between programmes in EU countries are found, further study on the relative costs and effectiveness of the different approaches to screening will be necessary.
Methods
Drawing particularly from five major cost-effectiveness analyses, 20, 21, [23] [24] [25] we selected the following items to formulate vision (Q1) and hearing (Q2) screening questionnaires:
. Questions formulated in a focus group were structured as multiple-choice with room for comments and multiple answers (See Appendix, Q1, Q2). All forms of screening for vision or hearing problems were included (eg. inspection of the eyes was also counted as form of vision screening). To obtain a broader perspective of screening systems, a short public health questionnaire (Appendix Q3) to provide background information on screening and screening systems in all countries was developed through extrapolation of the vision and hearing questionnaires.
In each of the 28 EU full member states, five candidate states, potential candidate state Albania and associated states Israel, Moldova, Norway, and Switzerland, a paediatric ophthalmologist, orthoptist, otolaryngologist, audiologist, and screening professional were selected, based on their involvement in paediatric vision and hearing screening, and asked to complete the questionnaires for their own country. Public health representatives were identified through the Ministries of health or recommendation from the vision and hearing representatives.
The questionnaire included questions about screening tests, age, and frequency of screening. Different tests can be used to screen for one disorder, but screening programmes can also focus on more than one disorder. Two-stage or multiple-stage testing improves screening specificity but increases screening costs, although higher specificity can reduce diagnostic follow up costs. 23, 26 Questions about the range of professions involved in screening were included because this influences the quality and costs of screening. Screening tests with higher sensitivity and specificity might require more highly educated personnel and higher salary costs, which will increase the costs of screening. This increase in costs should be balanced with the increase in sensitivity and specificity. aABR: automated Auditory Brainstem Response; detects responses in the brainstem after offering clicks of 35 or 40 dB via headphones. Amblyopia (lazy eye): reduced vision, usually in one eye caused by abnormal visual experience in early childhood e.g. strabismus and refractive error. Brü ckner test: A direct ophthalmoscope is used in a darkened room and the red reflex in both eyes is assessed simultaneously at 0.6 to 0.9 metres. The colour and brightness of the red reflexes are compared. The colour is often more orange than red. The test is easy and quick to perform and can reliably detect media opacities. Strabismus and refractive error can also be detected, but with a lower sensitivity. Refractive error can give a yellow-white edge to a red reflex. Hirschberg test: corneal light reflex test. The corneal light reflex test is performed to assess ocular alignment. The test is performed by shining a light into the child eyes from a distance and observing the reflections on the cornea with respect to the pupil. The location of the light reflexes should be symmetric. OAE: Otoacoustic emissions; sounds produced by inner ear hair cells if the hearing threshold is better than 35 dB and picked up by a microphone in the ear canal.
The questionnaire also covered funding sources, including state, regional, municipal, Health insurance, parental and/or charity. The choice of funding agencies will influence the equity of screening, competitiveness, costs, coverage, and cost-effectiveness. Questions about coverage were included because the participation frequency of a screening programme is crucial for its effectiveness, and to make screening worthwhile from a population perspective. Low coverage can lead to delayed provision of the correct treatment and increased disease burden. If screening is free or compulsory, coverage will be higher. Acceptable participation frequencies may be reached by incorporating screening into an existing system with a high participation rate, eg. vaccination programmes or school start.
Questionnaires were emailed from December 2013 until April 2014. Clinicians involved in population-based screening were identified and their answers were crosschecked with those given by general screening professionals. If answers were ambiguous the questionnaires were returned to both the clinician and the screening professional and they were asked to contact each other to agree corrections. Overviews of the questionnaire answers were circulated three times to all representatives. All representatives were asked to review and correct any errors in the overviews for their own and neighbouring countries. The overviews were also checked by external experts, involved first-hand in vision and hearing screening.
Results
In all 39 countries (including two separate regions, Flanders and Wallonia, in Belgium), representatives were found. Vision representatives were found in 36 countries, hearing representatives in 38, and public health representatives in 23 (Table 1 ).
Vision
Information on vision screening programmes was obtained from 36 countries including two Belgian regions. No information could be obtained from Albania, Macedonia, and Moldova. Thirty-five countries have a vision screening programme in place. In Belgium, Bulgaria, Estonia, France, Romania, Spain, and Switzerland this is a regional programme. In several countries with a national vision screening programme in place, regional differences in screening protocols exist.
Infant and preverbal screening tests. Infant screening (age 0-4 months) included inspection, fixation, red reflex testing, Hirschberg test, Bru¨ckner test, Cover test, pupillary reflexes, and motility. Most countries perform a combination of two or more of these tests. In Bulgaria, Greece, and Poland no infant screening is performed. In Germany only eye inspection is performed. In Ireland, Montenegro, and Spain, eye inspection is combined with red reflex testing. In Cyprus, Italy, Lithuania, and Malta only red reflex testing is done. In Latvia this is combined with motility testing. Preverbal screening (age 6-30 months) includes the same tests. Preverbal screening is not performed in eight countries, but most countries combine two or more tests.
Visual acuity (VA) measurements. In all countries VA is tested, but the age of the first measurement varies from 3-7 years. In a third of countries VA is tested once, one third twice, and in one third more than twice. In most countries, VA measurements are repeated at an older 
age. In children aged 4 and younger VA charts are most commonly picture charts and the Lea Hyvarinen chart, above age 4, Tumbling-E and Snellen are most often used.
Personnel and referral. Screening is mostly performed by paediatricians, ophthalmologists, and/or nurses. In most countries children are referred to ophthalmologists for further examination; in Latvia they are referred to the General Practitioner (GP), in the UK they may also be referred to joint orthoptic and optometry clinics or optometrists, in Malta to either the orthoptist or optometrist, and in the Netherlands they are mostly referred via the GP to an orthoptist or ophthalmologist, but sometimes directly to an orthoptist, ophthalmologist, optometrist, or optician. 
Hearing
Information on neonatal hearing screening programmes was obtained from 38 countries (including two Belgian regions). No information could be obtained from Macedonia. Nationwide UNHS programmes exist in 33 of 38 countries. Malta has nationwide selective screening only for infants from neonatal and paediatric IC units. In Bulgaria, Moldova, and Serbia local selective screening programmes for high risk groups (premature newborns) exist. In Albania a pilot nationwide UNHS programme was discontinued due to lack of funds.
Tests. The most widely used audiometric test is OAE. Flanders has used aABR in all neonates, but in 2013 introduced additional auditory steady state responses (ASSR). Some regions in Denmark, Estonia, France, Germany, Spain, and Sweden use aABR, OAE, or both in the same infant as first test in healthy babies. In nearly all programmes both ears are tested, except in Finland and Switzerland, where one or two ears are tested, depending on the institution or the presence of risk factors. Testing is not staged in five countries, two-staged in 13 countries, three-staged in 19 countries, and 4-staged in one country. aABR is used as final stage in the majority of countries. In high risk groups, eg. premature newborns, most programmes use aABR or a combination of OAE and aABR, but in eight countries OAE only is used. In Wallonia (Belgium) all premature infants undergo full ABR. In less than half of the countries, a hearing test in preschool or early school age children is a regular part of health screening programmes.
Referral. Neonates who do not pass the test are referred to a combined audiology/ ear, nose, throat (ENT) institution in most countries, in some countries to an audiologist, and in a few countries to an ENT specialist.
Funding. In most countries the government or health insurance finances the neonatal hearing screening programme. Other reported funding includes hospital, parents, and private funds.
Coverage. UNHS programmes cover an estimated 10-50% in Romania, 50-95% in nine countries, and more than 95% in 23 other countries. Malta has a nationwide selective screening programme with good coverage, whereas Bulgaria, Moldova, and Serbia have local selective screening programmes, with low coverage. Albania's discontinued pilot nationwide UNHS programme had a low coverage. Further detail is available in table 3 and Appendix Map 2.
Public health
Extra information on public health screening programmes was obtained from 23 countries including one Belgian region (Flanders). All have a public health screening programme, but in Albania, Belgium, and Spain this is a regional programme. In the Netherlands and Sweden a combination of national and regional programmes exists. Almost all countries have a programme for all children, except Albania, where screening is selective. Screening is not free in Albania, Bulgaria, and Czech Republic, and is compulsory in Bulgaria, Flanders, Greece, Hungary, and Turkey.
Tests. Weight, height and head circumference are measured in all countries, cardiac function in all but Albania, lung function in all but Albania and Flanders, vision in all but Albania and Turkey, hearing in all but Albania and Malta, motor skills in all but Czech Republic and the UK, speech and language development in all but Albania, Bulgaria, Czech Republic, and the UK, cognitive development in all but Albania, Czech Republic, Flanders, and the UK. Psychosocial development is assessed in all countries but Albania, Bulgaria, Czech Republic, Flanders, Germany, Israel, Sweden, and the UK.
Referral, funding and coverage. Referral is most often to a specialist. Funding is provided mostly by the government 
Questionnaire answer check
Changes were made based on the first round of questionnaire answers. In hearing screening data: for Belgium (Flanders) the ASSR was added as test for neonates at risk; for Finland ''testing one ear'' was changed to ''testing one ear or both ears''; for France ''testing one ear and testing both ears'' was changed to ''always testing both ears''; for Italy coverage of '' >95%'' was changed to ''70%''; Malta selective screening, not population-wide screening, was confirmed; for Poland ''non-staged screening'' was changed to ''staged screening''; for Israel, Italy, most difficult. Information on tests, personnel, and age was easier to acquire. Coverage may have been overestimated by the country representatives. Screening for vision and hearing deficits has similarities, but also differences. An essential difference is that objective tests are available for hearing screening at a very early age, enabling screening directly after birth. This is probably the reason for the more uniform approach and higher coverage reported for hearing screening compared with vision screening. We assumed that the personnel operating the screening apparatus at the hospital or during home visits would be a technician, so did not ask the profession explicitly. The only two tests for hearing screening are OAE and aABR, so the major difference in hearing screening is the number of stages before referral. Multiple stage screening is more expensive, but yields higher specificity, which reduces the number of false referrals to specialized and expensive audiological care centres. 23, 26 There are most frequently two or three stages of screening before referral, generally with OAE as the first test and aABR as last test. It has been suggested that three stages may be more cost-effective 26 , but this is not based on combined use of OAE and aABR. Pre-school or early school-age hearing tests may potentially discover hearing loss acquired during the years after birth, but this occurs rarely and these tests have been abolished in many European countries.
The wide differences between European screening programmes may have occurred because these programmes arose piecemeal, before robust evidence on effectiveness and cost-effectiveness was available to guide protocol design or implementation. In addition, most preventive health care programmes are government funded and, therefore, competition is lower than in curative healthcare. Further assessment is needed on the influence of funding source (eg. state, health insurance, or municipalities) on the efficiency of screening.
Further study should also be undertaken into the relative costs and effectiveness of different approaches to screening, as in Europe, 12 different VA charts are used, 10 professions are involved in vision screening, one to four hearing screening tests take place before referral, and eight funding sources are involved. The large number of screening tests used in vision screening should be compared. Efficiency of screening (ie. sensitivity and specificity per euro) should be calculated for screening performed by different screening professions.
We now plan to include data sources in a much larger and more detailed questionnaire. The EUSEREEN study group, an EU-wide consortium (see list at end of paper), is currently preparing a Europe-wide study to compare and optimize the cost-effectiveness of vision and hearing screening, and give country-specific advice in all candidate, associate, and full EU-member states.
